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Since the emergence of the so-called omics technology, thousands of putative biomarkers have been identified and
published, which have dramatically increased the opportunities for developing more effective therapeutics. These
opportunities can have profound benefits for patients and for the economics of healthcare. However, the transfer of
biomarkers from discovery to clinical practice is still a process filled with lots of pitfalls and limitations, mostly
limited by structural and scientific factors. To become a clinically approved test, a potential biomarker should be
confirmed and validated using hundreds of specimens and should be reproducible, specific and sensitive. Besides
the lack of quality in biomarker validation, a number of other key issues can be identified and should be addressed.
Therefore, the aim of this article is to discuss a series of interpretative and practical issues that need to be
understood and resolved before potential biomarkers become a clinically approved test or are already on the
diagnostic market. Some of these issues are shortly discussed here.
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Introduction
The strengthening of the robustness of discovery tech-
nologies, particularly in genomics, proteomics and me-
tabolomics, has been followed by intense discussions on
establishing well-defined evaluation procedures for the
identified biomarker to ultimately allow the clinical val-
idation and then the clinical use of some of these
biomarkers.
The ability of biomarkers to improve treatment and
reduce healthcare costs is potentially greater than in any
other area of current medical research. For example, the
American Society of Clinical Oncology estimates that
routinely testing people with colon cancer for mutations
in the K-RAS oncogene would save at least US $600 mil-
lion a year [1]. On the other side, thousand of papers in
the course of biomarker discovery projects have been
written, but only few clinically useful biomarkers have* Correspondence: kurt.krapfenbauer@boehringer-ingelheim.com
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distribution, and reproduction in any mediumbeen successful validated for routine clinical practice [2].
The following are the major pitfalls in the translation
from biomarker discovery to clinical utility:
1. Lack of making different selections before initiating
the discovery phase.
2. Lack in biomarker characterisation/validation
strategies.
3. Robustness of analysis techniques used in clinical
trials.
Each of these details is rarely documented and can
dramatically affect the predictive outcome of biomarker
results. However, the selection of useful biomarkers
must be carefully assessed and depends on different im-
portant parameters, such as on sensitivity (it should cor-
rectly identify a high proportion of true positive rate),
specificity (it should correctly identify a high proportion
of true negative rate), predictive value etc. Unfortunately,
biomarkers with ideal specificity and sensitivity are diffi-
cult to find. One potential solution is to use the com-
binatorial power of different biomarkers, each of whichoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Besides traditional immunoassays such as ELISA, recent
technological advances in protein chip and multiplex tech-
nology offer a great opportunity for the simultaneous ana-
lysis of a large number of different biomarkers in a single
experiment, which has expanded at a rapid rate in the last
decade. However, although many significant results have
been derived, one additional limitation has been the lack of
characterisation and validation of such technologies. Be-
sides technical characterisation, it also needs quality re-
quirements for correct characterisation of the predictive
value of biomarkers. In order to overcome these limitations,
some authorities (e.g. Food and Drug Administration
(FDA), European Medicines Agency (EMA), European
Association for Predictive, Preventive and Personalised
Medicine (EPMA), National Institute of Health (NIH))
already set up recommendations, short proposals and
minimum information about a variety of bio-analytical
experiments that describe the minimal requirements to
ensure that the technical performance as well as the
predicted value of biomarkers are correct. For example,
EPMA tries to outline a number of key issues in research,
development and clinical trial studies, including those
associated with biomarker characterisation, experimental
design, analytical validation strategies, analytical complete-
ness and data managements [3]. Actual paper follows
recommendation presented in the ‘EPMA White Paper’
[4]. Current recommendations should serve a set of cri-
teria, which will help to carry on to a high-quality data
project. Improvements in the quality outcomes are import-
ant because without requirements in the improved selec-
tion of biomarkers, correct performance of standardisation
and validation, the interpretation of the results as well as
the direct comparisons of the predictive value of bio-
markers between different research labs or clinical trial
studies is not possible. Besides the lack of quality in bio-
marker selection, a number of other key issues can be iden-
tified, which should be addressed in the course of this
article. Therefore, the aim of this article is to review and
discuss a series of interpretative and practical issues that
need to be understood and resolved before potential
biomarkers go into the market and become feasible diag-
nostic tools. The content and structure of the necessary in-
formation, as well as potential pitfalls and limitations of
biomarker research and validation, are discussed briefly in
the next subsection.
Short overview of different kinds of biomarkers
One of the goals of personalising medicine is to use the
growing understanding of biology so that patients receive
the right drug for their disease, at the right dose and the
right time. Although the definitions of personalising vary,
they all include the use of different biomarkers driven by a
decision-making process in which a diagnostic test ispivotal. Biomarkers include gene expression products,
metabolites, polysaccharides and other molecules such
as circulating nucleic acids in plasma and serum, single-
nucleotide polymorphism and gene variants. Ideal bio-
markers for use in diagnostics and prognostics, and for
drug development and targeting, are highly specific and
sensitive [5]. Biomarkers can also be categorised as phar-
macodynamic, prognostic or predictive [6]:
1. Pharmacodynamic biomarkers indicate the outcome
of the interaction between a drug and a target,
including both therapeutic and adverse effects [7].
2. Prognostic biomarkers were originally defined as
markers that indicate the likely course of a disease in
a person who is not treated [8]; they can also be
defined as markers that suggest the likely outcome of
a disease irrespective of treatment [9,10].
3. Predictive biomarkers suggest the population of patients
who are likely to respond to a particular treatment [8,9].
Predictive biomarkers help to assess the most likely re-
sponse to a particular treatment type, while prognostic
markers show the progression of disease with or without
treatment. In contrast, drug-related biomarkers indicate
whether a drug will be effective in a specific patient and
how the patient’s body will process it. Figure 1 gives an
overview of different biomarker categories and types.
In Figure 1, the clinical biomarkers for diagnostics de-
termine whether a patient is suitable for treatment with a
particular drug (by stratification markers), determine the
most effective dose for the patient (by efficacy markers),
determine the underlying susceptibility of a patient for a
particular side effect or group of side effects (by toxicity
markers) or evaluate the course and effectiveness end
point of a therapy (by surrogate endpoint markers).
Biomarkers can also be used as surrogate end points
(end points that substitute for a clinical outcome such as
how a patient feels or functions, or how many patients
survive) [9,11,12]. Another way of classifying biomarkers
is by their role in drug development. Pharmacokinetic or
pharmacodynamic biomarkers are involved in early pre-
clinical to phase I studies, and clinical (prognostic, pre-
dictive and surrogate) biomarkers play a role in phase II
and III trials [10].
The Biomarkers and Surrogate End Point Working
Group [13] has defined a classification system that can
be used for biomarkers [14]:
1. Type 0 consists of disease natural history biomarkers
that correlate with clinical indices;
2. Type I tracks the effects of intervention associated
with drug mechanism of action;
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Figure 1 Clinical biomarkers: categories/types.
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proteins) needs different diagnostic assays; therefore, dif-
ferent qualification and validation strategies are required.
Pharmaceutical companies are increasingly looking to
develop a drug and diagnostic test simultaneously, in a
process referred to as drug-diagnostic-co-development
so-called companion diagnostic (CDx), to better define
the appropriate patient population for treatment. CDx
are increasingly important tools in drug development
because they lead to the following:
1. Reduced costs through pre-selected (smaller) patient
population;
2. Improved chances of approval;
3. Significantly increased market uptake;
4. Added value for core business (late phase);
5. Regulatory trend to have CDx mandatory.
The first drug introduced using the personalised
medicine paradigm—Herceptin (Trastuzumab; Roche/
Genentech, South San Francisco, CA, USA)—has now
been on the market for more than a decade. However,
the number of drugs marketed alongside CDx remains
small (see Table 1).
Regulatory hurdles have been cited as other main rea-
sons for the slow growth in this area. The differences be-
tween the regulatory process in the European Union
(EU) and USA and the complexities of the regulatory
processes in both regions cause other huge problems for
companies. These difficulties affect the preparation of
dossiers and their timing and are amplified when con-
sidering a CDx project, particularly where more than
one company (e.g. pharmaceutical and diagnostic com-
panies) is involved.Advances in the science underlying drug development
have made the discovery of novel biomarkers a real
possibility, whilst still challenging, and the use of bio-
markers to drive drug development programmes has
been increasing steadily over the past decade. Whilst the
majority of these biomarkers will not be translated into
CDx tests, the growth of biomarker use indicates that
the future of the industry will lie in personalised
medicine.
As reflected in Figure 2, the search of the scientific lit-
erature indicates that many studies report the discovery
of different potential biomarkers, but most of them do
not meet the criteria of high sensitivity and specificity.
The lack of sensitivity and/or specificity leads to a low
number of patent application and, in addition to this, to
a low number of successful market applications.
If the biomarker used for patient selection is known
from the earliest stages of the development process, the
process of assay development can begin early, and there
will be a selection of diagnostic assay used in clinical
trials from an early stage. Biomarkers related to response
to therapy are often the result of clinical investigations
in patients and may not be available until later in the de-
velopment programme.
Diagnostic development is undertaken in three stages
once a biomarker has been identified. Analytical valid-
ation ensures the consistency of the test in being able to
measure the specific biomarker. Clinical validity relates
to the consistency and accuracy of the test in predicting
the clinical target or outcome claimed, and clinical util-
ity relates to the fact that the test should improve the
benefit/risk of an associated drug in the selected and
non-selected groups. Table 2 describes strategic consid-
eration and implication positions of key stakeholders—
Table 1 Overview of already approved CDx on the markets
Biomarker Related drug Company Indication Test
Her-2/neu Herceptin Genentech/Roche Breast cancer PathVysionWFISH
Kit (CD117) Gleevec/Glivec Novartis Gastrointestinal c-Kit pharmDx
EGFR Erbitux/Tarceva Bristols-Myers/Genentech Colorectal/NSCLC EGFR pharmDx kit
CD20 Rituxan/Bexxar Genentech/Glaxo NHL Flow cytometry
CD25 Ontak/Onzar Eli Lilly Lymphoma Flow cytometry
CD33 Mylotarg Wyeth Leukaemia, CML Flow cytometry
Estrogen receptor Nolvadex AstraZeneca Breast cancer Hormone receptor assay
HLA A2/HLA C3 Melacine GlaxoSmithKline Melanoma Serology, DNA-based
Philadelphia chromosome Roferon-A/Gleevec/Glivec Roche/Novartis Leukaemia, CML BCR-ABL chromosome translocation test
T(15;17) translocation Trisenox Cephalon Leukaemia, CML Fluorescence in situ hybridisation (FISH)
PML/RAR-α gene expression Vesanoid Roche Leukaemia, CML
EGFR, epidermal growth factor receptor; CML, chronic myelogenous leukaemia; NSCLC non-small-cell lung carcinoma; NHL, non-Hodgkin lymphoma.
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physicians and healthcare providers.
Case studies of drugs and their companion diagnostics
that have been approved over the last 10 years indicate that
the number of co-developed products is small. The major-
ity of diagnostic tests available to drive patient selection for
particular drugs have been added years after the drug’s
approval. However, experience from the EU and USA also
indicates that regulators will not approve targeted drugs in
the absence of available, relevant diagnostic tests.
Key points to be addressed
According to Issaq et al. [5], the failure in finding high-
sensitive and high-specific biomarkers may be attributed
to the following factors:
1. Small number of samples that are analysed;
2. Lack of information on the history of the samples;Year 2002 2003 2004 2005
Biomarkers Publikation 625 1087 1478 1920
Biomarker Patents 50 74 95 180
Figure 2 Overview of the relationship between publications and pate3. Case and control specimens which are not matched
with age and sex;
4. Limited metabolomic and proteomic coverage; and
5. The need to follow clear standard operating
procedures for sample selection, collection, storage,
handling, analysis and data interpretation.
Furthermore, most studies to date used samples with a
complex matrix such as serum, plasma, urine or tissue
from patients and controls. Another reason for pitfalls in
biomarker validation is the usually slow progression of
some diseases, requiring high numbers of well-stratified
patients who are undergoing long-term treatment when
conventional diagnosis and imaging techniques are used.
Importantly, there is a lack of sensitive and specific
prognostic biomarkers for disease progression or regres-
sion that would permit a rapid clinical screening for po-
tential responders and non-responders. Nonetheless, in2006 2007 2008 2009 2010 2011
2661 3270 4168 5033 6208 7720
238 320 396 593 471 407
nting of biomarkers.
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a positive impact on morbidity and mortality of chronic
diseases, the field is now moving more quickly towards
clinical translation. This development is driven by smart
preclinical validation, a better study design and improved
surrogate readouts using currently available methodolo-
gies and diagnostic techniques. Moreover, upcoming novel
biomarkers and diagnostic technologies will soon permit a
more accurate and efficient assessment of disease progres-
sion and regression.
Considerations before initiating the biomarker discovery
phase
Although some biomarkers have been approved by the
FDA as qualitative tests for monitoring specific diseases
(e.g. nuclear matrix protein-22 for bladder cancer), unfor-
tunately, the majority of found biomarkers (proteins or
metabolites) are not sensitive and/or specific enough to be
used for population screening. One of the major reasons
that proteomic and metabolomic studies over the past dec-
ade have failed to discover molecules to replace existing
clinical tests is due to errors in either study design and/or
experimental execution. Werner Zolg wrote in a review
[15] that, before initiating the discovery phase, the first step
in the process chain of creating new diagnostic content is
to make critical decisions on the sample selection that will
directly impact the outcome of the identification process.
The very selection of the discovery samples and their
degree of characterisation of the material, down to thestandard operation procedures on how the samples were
acquired and stored, can be decisive for success or failure.
By selecting tissue as the discovery material for biomarker
identification, one must inevitably choose between cultured
cells or specimen directly obtained from patients. There
are advantages/limitations to either option.
Consideration on the selection and randomisation of
patients for biomarker studies: looking for the ‘ideal’
patients
The optimal selection and randomisation of patients is es-
sential and has to be included in each clinical trial, testing
the efficacy of drugs and biomarkers. In particular, given
the variant course of disease progression even in well-
selected patients with a dominant single aetiology, sub-
jects should be well matched according to factors such as
the following lifestyle risk factors: (1) alcohol and tobacco
consumption, (2) body mass index, (3) physical activity,
(4) signs of the metabolic syndrome or (5) use of (over-
the-counter) medications. As in other studies, age and sex
should be balanced. In addition, stratification of patients
as to their genetic risk of developing a specific disease,
(e.g. using a score) will be central to obtaining a balanced
randomisation of the placebo vs. the treatment group.
These facts alone should significantly reduce the number
of patients and the duration of the trial needed to demon-
strate a significant reduction of disease progression or in-
duction of regression. Histological end points in proof-of
-concept trials will still be required by regulatory author-
ities, apart from long-term hard end points, such as mor-
bidity and mortality in phase III trials. At present, it is not
possible to exactly predict the number of patients and the
time on treatment that are needed to demonstrate the
clinical benefit of a drug agent or biomarker. This is one
major reason that companies have been reluctant to enter
this difficult field.
The current state of biomarker discovery
The search of the scientific literature clearly indicates
that most published biomarkers are inadequate to re-
place an existing clinical test or that they are only useful
for detecting advanced disease stage, where the survival
rate is low. Many molecular or genetic biomarkers have
been suggested for the detection of different diseases;
however, most of them do not possess the required sen-
sitivity and specificity. Another reason why most pro-
posed metabolomic and proteomic biomarker results that
have not progressed from the laboratory to the clinic
study is that the majority stopped at the first phase of bio-
marker discovery. According to other studies [5,16,17],
there are five phases that a protein or a metabolite has to
go through to become a biomarker. Phase I is preclinical
exploratory studies to identify potentially useful markers,
phase II is clinical assay development for clinical disease,
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phase IV is prospective screening studies and phase V is
control studies [5].
Listed examples of already approved biomarkers in
Table 1 show that there are no 100% sensitive and spe-
cific biomarkers for different types of diseases to date. A
biomarker with a high sensitivity has a low specificity
and vice versa. Unfortunately, biomarkers with ideal spe-
cificity and sensitivity are difficult to find. One potential
solution is to use the combinatorial power of a number
of different biomarkers, each of which alone may not
offer satisfactory in specificity. For example, Horstmann
et al. [18] studied the effect of using a combination of
bladder cancer biomarkers on sensitivity and specificity.
Although none of the combinations resulted in 100%
sensitivity and specificity, the sensitivity improved from
91% (using two biomarkers) to 98% using a combination
of four different biomarkers.
Pitfalls and limitations
However there exist different reasons why most potential
biomarkers failed in achieving adequate sensitivity and
specificity and are not accepted as clinical tests. One main
reason is that most biomarkers are dealing with detecting
diseases at an early stage in humans that have different
age, sex and ethnicity. Other important fact is to find a
protein or a metabolite at an extremely low concentration
level among thousands of other proteins and metabolites.
To improve sensitivity and specificity, there are different
strategies: potential solutions are listed as follows:
1. Improve the assay (e.g. antibody with a higher
specificity and/or in combination with a detection
conjugate with a higher sensitivity),
2. Combine several markers,
3. Check for subpopulations and stratify population
(e.g. matched by gender, age, pathology).
The current procedure for the search of biomarkers is
dealing with potential errors in the study design that can
be avoided in future studies.
Figure 3 gives an overview about two main reasons why
most potential biomarkers failed in achieving adequate
sensitivity and specificity and are not accepted as clinical
tests. One main reason is pitfalls and limitations in bio-
marker discovery and second main reason is pitfalls in
biomarker validation.
Age, sex and race
Biomarker studies are normally carried out using body
fluids or tissues collected from patients and healthy subjects
of different ages, sex and race. Using samples from patients
and controls that are of different ages and sexes can dra-
matically influence the results. In a recent study, Lawtonet al. used 269 subjects, 131 males and 138 females, to
study the effects of age, sex and race on plasma metabolites.
The patients were of Caucasian, African-American and
Hispanic descent and ranged in age from 20 to 65 years.
The subjects were divided into three different age
groups; 20–35, 36–50 and 51–65. Using GC/mass spec-
trometry (MS) and high-performance liquid chromatog-
raphy (HPLC)/MS, they reported that ‘more than 300
metabolites were detected of which more than 100
metabolites were associated, with age, many fewer with
sex and fewer still with race’ [19].
Selection of patients and controls
Patients for biomarker studies should be carefully selected
by a specialist (e.g. oncologist for cancer studies or a path-
ologist for tissue samples) to insure the presence or ab-
sence of diseases. Unfortunately, predictive curve values of
biomarkers with no or less overlapping of diseased vs.
non-diseased cohorts are difficult to find. There exist al-
ways more or less overlapping areas between healthy and
diseased cohort. The overlapping area allows the analyst
to calculate the proportion of patients whose diagnosis
was correctly predicted by the model (true positives for
sick patients and true negatives for healthy patients) or
false negative or false positive values [3].
Generally, the number of patients and control subjects in
published studies is very small to give an acceptable statis-
tical value. Also, many of the potential proposed markers
have not been confirmed or validated in a high-quality
manner. Body fluids and tissues are collected from a group
of patients of different disease stages, and results are
compared with a group of healthy persons. The effect of
a disease stage on sensitivity of a single biomarker should
be taken into consideration as mentioned previously be-
cause sensitivity improves with increase in disease stage.
Grossman [20] adequately summarises the importance of
consistency through his observation that ‘the contradicting
published reports likely [resulted] from studies testing dif-
ferent patient populations, using different methodologies,
and applying different [cut-offs] for a positive test’.
Errors in study execution
Study execution deals with experimental parameters that
need to be considered. These parameters include many dif-
ferent variables, such as sample collection, handling and
storage, sample comparison, number of samples, sample
preparation, methods of analysis and number of replicates.
Sample collection, handling and storage
Samples are collected from a person who passed a phys-
ical exam by a physician who determines that the person
of interest has a concrete disease or is healthy. Samples
(serum, plasma, urine, saliva, tissue etc.) should be col-
lected in freezer-type tubes, immediately snap frozen and
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Figure 3 Pitfalls and failures in biomarker identification.
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mended that, for short-time storage (less than 1–2 weeks),
storage condition should be at −20°C, and for long-term
storage (more than 2 weeks), storage condition should be
at −70°C. At the time of analysis, samples should be
thawed at 4°C or on ice and prepared according to the
selected method of analysis. The history of the sample is
very important and may have been obtained from sample
storage banks with proper collection, storage information
about the stage of disease, medication, pathology, age,
gender and condition of patients. A lack of consistency in
sample collection and storage can doom a study before
any data are even collected.
Direct sample comparison
If this option is chosen, the degree of sample character-
isation is critical. It is of importance that the specimens
used in the diseased cohort are not simply classified as
‘diseased’ (if possible, together with the stage of the dis-
ease) but that a detailed histopathological assessment of
the distribution of cell types (e.g. tumour cells, necrotic
cells, stroma) in the diseased specimens is carried out
[5]. This distribution should be as uniform as possible in
all samples, and it should represent the correct disease/
healthy state. Otherwise, normalising the analytical out-
come becomes very difficult.Number of samples
The number of samples that have to be placed in the dis-
eased and healthy control groups in order to be compared
with a variety of analytical approaches remains a matter
of discussion. A minimum of 15 samples in the discovery
phase is necessary to get a reasonable representative selec-
tion basis for marker candidates. If the number is for prac-
tical reasons (resources, cohort and time lines), which is
very small (e.g. less than 10 per group), then the observed
differences between the two sets of specimens are in dan-
ger of being over-interpreted when extrapolated to
generalised cohorts. Low sample sizes make the correct
identification of those differences increasingly difficult. To
overcome these limitations, Zolg [15] recommended run-
ning second and third discovery rounds to complement
the results of the first round. Ideally, the sample number
analysed should not only allow stating the presence or ab-
sence of a given protein, but should also give the oppor-
tunity to identify trends. Another opportunity is to pool
the samples, i.e. to physically combine several of the ex-
tracts to create fewer samples, to be put through the en-
tire analytical process. Pooling of samples inevitably leads
to a loss of information. The distribution of proteins is
averaged by the very pooling process with the prospect
that individual proteins are pushed below the detection
limit by one member of the pooling cohort not expressing
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lection process, the individual spectrum of proteins has to
be established. Therefore, the pooling process just shifts
the workload to a later point in the process chain, and
very good arguments have to be found to deliberately in-
crease the complexity of the data sets by pooling.
Sample preparation
Preparations of the sample for proteomic and meta-
bolomic analyses prior to analysis are very important and
can introduce errors that always will affect the final results
[3,5]. The search for biomarkers in biological samples
involves different steps depending on the sample type and
if it is analysed for metabolites or proteins. Extraction of
metabolites from the blood, urine or tissue required mul-
tiple purification and extraction procedures using different
solvent systems as discussed by Want et al. [21] and Issaq
et al. [5]. It is not always possible to extract or to isolate
all the metabolites from a sample with a single solvent
since metabolites have different chemical and physical
properties and are present in a wide dynamic range of
concentrations. The search for a protein biomarker in-
volves extraction of the proteins followed by fractionation,
purification, specific enrichment and then analysis by dif-
ferent analytical methods (e.g. 2DE-PAGE, immunoassays,
Western blot, HPLC/MS/MS). Analysis of the blood as
well as the serum is more complicated than that of urine
or saliva as it contains fewer proteins, and high-abundant
protein must be depleted prior to analysis. Approximately
99% of the protein content of the blood (both serum and
plasma) is made up of only about 20 proteins (www.
plasmaproteome.org) [22]. While depletion of these pro-
teins will allow the detection of low-abundant proteins, it
may remove proteins that are bound to these 20 proteins,
resulting in a loss of potentially important information
[23]. Tissues are homogenised first followed by metabo-
lites, and proteins are extracted and analysed. Incomplete
homogenisation can lead to losses that can affect the
accuracy of the results. In addition, one cannot ignore
human errors in sample collection, storage, weighing, ex-
traction etc.
Methods of analysis
Choosing the optimal analysis method is critical in bio-
marker search by proteomics and metabolomics. For ex-
ample, analysing the plasma proteome involved protein
precipitation and solubilisation; therefore, the downstream
fractionation method must be either electrophoresis or a
liquid-phase method. Unfortunately, studies have shown
that the proteome analysis by groups using different
methods resulted not only in different numbers of protein
identifications, but also in poor overlap between the re-
sults [5,23,24]. These results prove that the selected
method of analysis is an important parameter.Number of replicates
Sample should be analysed in triplicate and report the
mean and standard deviation. Unfortunately, most pub-
lished proteomic and metabolomic studies only analyse
each sample once, which does not permit the deviation
from the mean (i.e. the error in the measurement) to be
calculated. Proteomic analysis of a biological sample
involves different analytical steps in the course of sample
preparation. Each one of these steps can introduce an
error. Due to difficulties either in sample preparation, in
protein preparation or in assay or protein chip hybridisa-
tion, the amount of replicas varied from zero to six. Thus,
implicating different optimal statistical tests were neces-
sary for the various settings.
Consideration on the improvement of current efficacy
readouts by development of non-invasive diagnostic
tools
Further improvement is desirable to reduce the number
of study patients, trial duration, costs and, most import-
antly, possible risks for individuals. Thus, new innovative
diagnostic techniques are needed that allow an exact as-
sessment of the degree of disease and, more importantly,
of the dynamic processes underlying the diseases. Such
biomarkers and technologies will have to be specific for
the targeted structure, i.e. the cells or key molecules
involved in the development of the disease. Ideally, sen-
sitive and specific markers/imaging methodologies will
allow a rapid and mechanism-based screening for and
efficacy monitoring of treatments. Additionally, there is
a need for universal-standardised reporting methods to
aid interpretation and comparison of potential clinical
biomarker trails. All current non-invasive methodologies
(serum markers, serum marker algorithms, contrast im-
aging etc.) yield a sufficient to excellent diagnostic ac-
curacy for the detection (or exclusion) of an upcoming
or current disease.
Regulatory outlook and future aspects
The regulatory landscape for biomarker discovery and
validation projects (especially for drug-diagnostic co-
development = companion diagnostic) is evolving and
getting more important to the upcoming clinical trial
studies. In the past few years, available data have been
reviewed by FDA and EMA, and experience from some
exploratory data submission process was used to create
a formal biomarker qualification purpose [25].
Both the FDA and EMA have similar biomarker quali-
fication processes in place that enable research institutes
and pharmaceutical companies to obtain advice or quali-
fication of the biomarker in question. In both cases,
similar guidance concepts were developed that are very
clear on the fact that biomarker qualification does not
constitute a review of a diagnostic for commercialisation.
Table 3 Molecular diagnostic players with approved tests







Gen-Probe CA, USA 18




AdvanDx MA, USA 10
Abbott Molecular IL, USA 8 15%
Hologic MA, US 7
Nanosphere IL, USA 7
Qiagen Germany 7
Idaho Technology UT, USA 5







IL, USA 3 15%a
Others 28
Total 153
aMainly imaging technology. After Datamonitor; adapted from the Association
of Molecular Pathology.
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missions are strongly recommended by US and EU au-
thorities and will be more and more required for drug/
diagnostic co-development projects in both regions [25].
Further guidance on clinical trial enrichment and in-
ternal standard operating procedures for cross-labelling
efforts are also expected and will improve the penetra-
tion of personalised medicine in clinical practice.
The FDA’s first guideline was finalised in 2005, and it is
based on the fact that many clinical trial studies were
utilising biomarkers but that these data were often ex-
ploratory and that their regulatory submission was not
required [25]. However, the US regulatory agency re-
garded the submission of these data as beneficial for both
the industry and the FDA to ensure that regulatory scien-
tists are familiar with and are prepared to evaluate future
submissions. This data mainly includes pharmacogenomic
information, and the programme is referred to as a volun-
tary exploratory data submission (VXDS). The success of
this VXDS programme has led to the development of a
number of new (draft) guidance documents including
those related to the biomarker qualification process and to
clinical pharmacogenomics in the early phases of drug de-
velopment. Further guidance on clinical trial enrichment
and internal standard operating procedures for cross-
labelling efforts within FDA offices is also expected and is
continuously under discussion.
Since the FDA’s initial publication, the International
Committee on Harmonisation (ICH) has published a
guidance relating to pharmacogenomic data (ICH E15)
that defines pharmacogenomics, pharmacogenetics, gen-
omic biomarkers, and relevant sample and data coding.
Standardised terminology is presented for incorporation
in future regulatory documents related to pharmacogen-
etics and pharmacogenomics. Further ICH guidance,
topic E16, on the information required for biomarker
qualification was published in 2010. In addition, the FDA
has established processes for working jointly with EMA
on the review of exploratory information. A review of
their experience and the impact of the guidance were
published in 2010 [16].
Conclusions
While application of potential biomarkers in preclinical
development is far advanced, only a handful have passed
clinical trials (see Table 1) and are already commercially
successful on the market (see Table 3). Reasons for the
pitfalls are manifold, including difficult validation strat-
egies and the usually slow disease progression, requiring
high numbers of well-stratified patients undergoing long-
term treatment when conventional diagnostic parameters
or related end points are used. Importantly, there is a no-
torious lack of sensitive and specific surrogate biomarkers
for disease progression or regression that would permit arapid clinical screening for potential drug candidates.
Nonetheless, in view of an urgent need for new drugs that
positively impact morbidity and mortality of different
diseases, the biomarker field is now moving more quickly
towards clinical translation. This development is driven by
thoughtful preclinical validation, a better study design and
improved surrogate readouts using currently available
methodologies. Moreover, upcoming novel biomarkers
and imaging technologies will soon permit a more exact
and efficient assessment of disease diagnosis, disease pro-
gression and disease regression as already published in
other works [26,27].
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